BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 362
- Registration Number
- NCT00631969
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 103
- Registration Number
- NCT00631124
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT00629837
Sorafenib Long Term Extension Program
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 206
- Registration Number
- NCT00625378
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 343
- Registration Number
- NCT00623467
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸University of South Florida, Tampa, Florida, United States
🇦🇷Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 143
- Registration Number
- NCT00623727
Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 453
- Registration Number
- NCT00624130
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 84
- Registration Number
- NCT00623480
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT00622479
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT00621673
© Copyright 2024. All Rights Reserved by MedPath